74 related articles for article (PubMed ID: 21136699)
1. A native antigen "reverse capture" microarray platform for autoantibody profiling of prostate cancer sera.
Ehrlich JR; Caiazzo RJ; Qiu W; Tassinari OW; O'Leary MP; Richie JP; Liu BC
Proteomics Clin Appl; 2007 May; 1(5):476-85. PubMed ID: 21136699
[TBL] [Abstract][Full Text] [Related]
2. Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling.
Qin S; Qiu W; Ehrlich JR; Ferdinand AS; Richie JP; O'leary MP; Lee ML; Liu BC
Proteomics; 2006 May; 6(10):3199-209. PubMed ID: 16596707
[TBL] [Abstract][Full Text] [Related]
3. The 'reverse capture' autoantibody microarray: a native antigen-based platform for autoantibody profiling.
Ehrlich JR; Qin S; Liu BC
Nat Protoc; 2006; 1(1):452-60. PubMed ID: 17406268
[TBL] [Abstract][Full Text] [Related]
4. The "reverse capture" autoantibody microarray : an innovative approach to profiling the autoantibody response to tissue-derived native antigens.
Ehrlich JR; Tang L; Caiazzo RJ; Cramer DW; Ng SK; Ng SW; Liu BC
Methods Mol Biol; 2008; 441():175-92. PubMed ID: 18370319
[TBL] [Abstract][Full Text] [Related]
5. Serum-autoantibodies for discovery of prostate cancer specific biomarkers.
Massoner P; Lueking A; Goehler H; Höpfner A; Kowald A; Kugler KG; Amersdorfer P; Horninger W; Bartsch G; Schulz-Knappe P; Klocker H
Prostate; 2012 Mar; 72(4):427-36. PubMed ID: 22012634
[TBL] [Abstract][Full Text] [Related]
6. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
Paus E; Nilsson O; Børmer OP; Fosså SD; Otnes B; Skovlund E
J Urol; 1998 May; 159(5):1599-605. PubMed ID: 9554362
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
8. Different perforin expression in peripheral blood and prostate tissue in patients with benign prostatic hyperplasia and prostate cancer.
Tokmadžić VS; Tomaš MI; Sotošek S; Laškarin G; Dominović M; Tulić V; Dorđević G; Sustić A; Mrakovčić-Šutić I
Scand J Immunol; 2011 Oct; 74(4):368-76. PubMed ID: 21535078
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
[TBL] [Abstract][Full Text] [Related]
10. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
11. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
Stamey TA; Warrington JA; Caldwell MC; Chen Z; Fan Z; Mahadevappa M; McNeal JE; Nolley R; Zhang Z
J Urol; 2001 Dec; 166(6):2171-7. PubMed ID: 11696729
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
14. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
15. Serum autoantibody biomarkers for age-related macular degeneration and possible regulators of neovascularization.
Morohoshi K; Patel N; Ohbayashi M; Chong V; Grossniklaus HE; Bird AC; Ono SJ
Exp Mol Pathol; 2012 Feb; 92(1):64-73. PubMed ID: 22001380
[TBL] [Abstract][Full Text] [Related]
16. Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis.
Sinha AA; Sackrison JL; DeLeon OF; Wilson MJ; Gleason DF
Anat Rec; 1996 Aug; 245(4):652-61. PubMed ID: 8837723
[TBL] [Abstract][Full Text] [Related]
17. Native antigen fractionation protein microarrays for biomarker discovery.
Caiazzo RJ; O'Rourke DJ; Barder TJ; Nelson BP; Liu BC
Methods Mol Biol; 2011; 723():129-48. PubMed ID: 21370063
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer.
Bradford TJ; Wang X; Chinnaiyan AM
Urol Oncol; 2006; 24(3):237-42. PubMed ID: 16678056
[TBL] [Abstract][Full Text] [Related]
19. Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity.
Barbero G; Destefanis P; Procida S; Mandili G; Ulliers D; Ceruti C; Fiori C; Maule MM; Fontana D; Giribaldi G; Turrini F
BJU Int; 2008 Dec; 102(11):1566-72. PubMed ID: 18549428
[TBL] [Abstract][Full Text] [Related]
20. The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer.
Patel K; Whelan PJ; Prescott S; Brownhill SC; Johnston CF; Selby PJ; Burchill SA
Clin Cancer Res; 2004 Nov; 10(22):7511-9. PubMed ID: 15569981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
